Puma Biotechnology Management
Management Kriterienprüfungen 4/4
Puma Biotechnology CEO ist Alan Auerbach , ernannt in Sep 2010, hat eine Amtszeit von 15.67 Jahren. Die jährliche Gesamtvergütung beträgt $3.06M , bestehend aus 30.4% Gehalt und 69.6% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 13.84% der Aktien des Unternehmens, im Wert von $51.23M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 8.3 Jahre bzw. 9.5 Jahre.
Wichtige Informationen
Alan Auerbach
Geschäftsführender
US$3.1m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 30.41% |
| Amtszeit als Geschäftsführer | 15.7yrs |
| Eigentum des Geschäftsführers | 13.8% |
| Durchschnittliche Amtszeit des Managements | 8.3yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 9.5yrs |
Jüngste Management Updates
Recent updates
Narrativ-Update • May 19
PBYI: 2026 Profit Outlook Will Likely Fail To Justify Current Pricing
Analysts have adjusted their price target on Puma Biotechnology to reflect updated views on fair value at $5.00. This change is accompanied by revised assumptions regarding the discount rate, revenue growth, profit margins, and a higher future P/E multiple.Analyseartikel • May 15
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
Puma Biotechnology, Inc.'s ( NASDAQ:PBYI ) earnings announcement last week didn't impress shareholders. However, our...Analyseartikel • May 11
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
A week ago, Puma Biotechnology, Inc. ( NASDAQ:PBYI ) came out with a strong set of first-quarter numbers that could...Narrativ-Update • Apr 28
PBYI: 2026 Profit Outlook Will Likely Fail To Justify Current Pricing
Analysts have adjusted their price target on Puma Biotechnology slightly, with the updated fair value moving to $5.00. This reflects refreshed views on the discount rate, long-term revenue growth, profit margins, and future P/E assumptions.Narrativ-Update • Apr 11
PBYI: 2026 Profitability Guidance Will Likely Fail To Support Current Pricing
Analysts have slightly adjusted their price target on Puma Biotechnology, keeping fair value around $5.00 while fine tuning inputs such as discount rate, revenue growth, profit margin, and future P/E to reflect updated assumptions about the company’s risk profile and earnings potential. What's in the News Puma Biotechnology issued new earnings guidance for the first quarter of 2026, projecting net product revenue of US$36 million to US$39 million and royalty revenue of US$2 million to US$3 million, for total revenue of US$38 million to US$42 million, with an expected net loss of US$8 million to US$10 million (company guidance).Narrativ-Update • Mar 28
PBYI: 2026 Guidance Will Likely Fail To Justify Current Pricing
Analysts have modestly adjusted their price target on Puma Biotechnology, reflecting small refinements to assumptions around the discount rate, revenue growth, profit margins, and forward P/E rather than a major shift in the outlook. What's in the News Puma Biotechnology issued earnings guidance for the first quarter of 2026, projecting net product revenue of US$36 million to US$39 million and royalty revenue of US$2 million to US$3 million, for total revenue of US$38 million to US$42 million (Key Developments).Narrativ-Update • Mar 13
PBYI: Index Inclusion Will Likely Fail To Offset Weak Revenue Outlook
Analysts have trimmed their price target on Puma Biotechnology to $5.00 from $5.00 in response to updated assumptions regarding discount rates, revenue growth, profit margins, and future P/E. These changes leave the fair value estimate effectively unchanged.Narrativ-Update • Feb 26
PBYI: Index Addition And Refined Assumptions Will Still Limit Upside Potential
Analysts have adjusted their price target on Puma Biotechnology to reflect an updated fair value of $5.00, a slightly lower discount rate of 7.25%, almost unchanged revenue growth at about 97%, a stable profit margin near 11.02%, and a marginally different future P/E of roughly 13.33x, indicating a largely intact valuation framework with only fine tuning to their assumptions. What's in the News Puma Biotechnology, Inc.Narrativ-Update • Feb 11
PBYI: Index Inclusion And Higher Multiple Will Likely Fail To Support Upside
Analysts have raised their price target on Puma Biotechnology to $5.00 from $3.50, citing updates to fair value estimates, discount rate assumptions, and expected future P/E levels. What's in the News Puma Biotechnology, Inc.Narrativ-Update • Jan 26
PBYI: Higher 2025 Guidance And Index Addition Will Not Sustain Current Optimism
Analysts have slightly adjusted their price target on Puma Biotechnology, citing modest tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E. Together, these changes translate into a small refinement in estimated fair value rather than a major reset in outlook.
Narrativ-Update • Jan 12
PBYI: Higher 2025 Guidance And Index Inclusion Will Still Look Overpriced
Analysts have lifted their price targets on Puma Biotechnology, citing updates to their models that reflect a fair value estimate of $5.00, adjusted discount rates, revised revenue growth assumptions of about 1% instead of a 3% decline, higher projected profit margins of around 10% compared with about 3%, and a lower assumed future P/E multiple near 14 versus about 37. What's in the News Puma Biotechnology, Inc.Narrativ-Update • Dec 26
PBYI: Raised 2025 Guidance Will Still Fail To Support Current Optimism
Analysts have modestly trimmed their price target on Puma Biotechnology to reflect a slightly lower future earnings multiple, even as estimates for fair value and long term growth remain largely unchanged. What's in the News Puma Biotechnology has been added to the NASDAQ Biotechnology Index, increasing its visibility among biotech-focused investors (index announcement).Narrativ-Update • Dec 12
PBYI: 2025 Revenue Guidance Will Fail To Justify Current Optimism
Analysts have modestly adjusted their price target on Puma Biotechnology higher, now seeing slightly improved valuation support in light of stable fair value estimates and marginally lower perceived risk in the companys long term outlook. What's in the News Puma Biotechnology issued new fourth quarter 2025 guidance, projecting total revenue between $67 million and $70 million and net income of $9 million to $11 million (company guidance).Analyseartikel • Dec 09
With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Narrativ-Update • Nov 27
PBYI: Rising Discount Rate Will Undermine Earnings Momentum In 2025
Analysts have slightly lowered their price target for Puma Biotechnology, citing marginal revisions in key financial estimates. This resulted in a new target of $3.50 per share, which remains unchanged from the previous assessment.Analyseartikel • Nov 13
Puma Biotechnology's (NASDAQ:PBYI) Shareholders May Want To Dig Deeper Than Statutory Profit
The market shrugged off Puma Biotechnology, Inc.'s ( NASDAQ:PBYI ) solid earnings report. We think that investors might...Seeking Alpha • Nov 10
Puma Biotechnology: Step By Step In Making A Transition
Summary Puma Biotechnology has been in something of a stasis for years, selling one drug with no new approvals while developing alisertib. The cash position remains strong enough to carry them through key readouts of the ALISCA trials. Two interim readouts guided in 1H 2026 will inform what is next for PBYI, and I think this has a lot of promise. Read the full article on Seeking AlphaNarrativ-Update • Nov 09
PBYI: Rising Discount Rate And Weak Revenue Outlook Will Pressure Earnings
Analysts have raised their price target for Puma Biotechnology from $3.00 to $3.50, citing improved revenue growth projections and stronger expected profit margins. What's in the News Puma Biotechnology issued new earnings guidance for the fourth quarter of 2025, projecting total revenue between $67 million and $70 million, and net income between $9 million and $11 million (Key Developments).Analyseartikel • Oct 18
Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 26% Though Its Price And Business Still Lag The Market
Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shares have continued their recent momentum with a 26% gain in the last month...Analyseartikel • Sep 11
Does Puma Biotechnology (NASDAQ:PBYI) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Aug 12
Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 43% Though Its Price And Business Still Lag The Market
NasdaqGS:PBYI 1 Year Share Price vs Fair Value Explore Puma Biotechnology's Fair Values from the Community and select...Analyseartikel • Aug 09
We Ran A Stock Scan For Earnings Growth And Puma Biotechnology (NASDAQ:PBYI) Passed With Ease
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analyseartikel • May 20
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Fly 25% But Investors Aren't Buying For Growth
Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shareholders have had their patience rewarded with a 25% share price jump in...Seeking Alpha • Apr 11
Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential
Summary Initiate coverage of Puma Biotechnology with a Hold rating due to limited near-term upside, competitive landscape, and uncertain pipeline outlook. NERLYNX adoption is hindered by side effects and competition, while alisertib is still in early development with modest expectations. Puma's cash runway may extend several years, but that could change with faltering revenues for NERLYNX, new drug additions, or other unforeseen pipeline developments. Legal issues and competitive pressures contribute to the cautious outlook, with no clear signs of growth or turnaround. Read the full article on Seeking AlphaAnalyseartikel • Mar 10
Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 26%
Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shares have had a really impressive month, gaining 26% after a shaky period...
Neues Narrativ • Feb 09
Alisertib Trials And International NERLYNX Approvals Will Expand Market, But Single Product Dependence And Safety Concerns Could Limit Gains
Strategic collaborations and regulatory approvals in international markets are expected to drive global revenue growth and increase overall sales.Analyseartikel • Jan 14
Insufficient Growth At Puma Biotechnology, Inc. (NASDAQ:PBYI) Hampers Share Price
You may think that with a price-to-sales (or "P/S") ratio of 0.6x Puma Biotechnology, Inc. ( NASDAQ:PBYI ) is...Seeking Alpha • Dec 16
Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward
Summary Puma Biotechnology focuses on expanding neratinib sales and developing alisertib for breast and lung cancers, despite recent stock declines. Neratinib sales are stagnant, but the company remains stable financially. Alisertib shows early efficacy signals, with phase 2 trials ongoing, but its future success remains uncertain. Despite market skepticism, I maintain a "Buy" sentiment due to PBYI's favorable financial status and potential growth from alisertib. Read the full article on Seeking AlphaAnalyseartikel • Nov 14
Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest
When companies post strong earnings, the stock generally performs well, just like Puma Biotechnology, Inc.'s...Analyseartikel • Sep 07
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Aug 15
Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop
To the annoyance of some shareholders, Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shares are down a considerable 26% in...Analyseartikel • Jun 07
The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%
To the annoyance of some shareholders, Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shares are down a considerable 25% in...Analyseartikel • Jun 05
Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$24m |
| Dec 31 2025 | US$3m | US$931k | US$31m |
| Sep 30 2025 | n/a | n/a | US$37m |
| Jun 30 2025 | n/a | n/a | US$48m |
| Mar 31 2025 | n/a | n/a | US$38m |
| Dec 31 2024 | US$4m | US$904k | US$30m |
| Sep 30 2024 | n/a | n/a | US$23m |
| Jun 30 2024 | n/a | n/a | US$9m |
| Mar 31 2024 | n/a | n/a | US$15m |
| Dec 31 2023 | US$3m | US$878k | US$22m |
| Sep 30 2023 | n/a | n/a | US$4m |
| Jun 30 2023 | n/a | n/a | -US$2m |
| Mar 31 2023 | n/a | n/a | US$5m |
| Dec 31 2022 | US$3m | US$852k | US$2k |
| Sep 30 2022 | n/a | n/a | US$10m |
| Jun 30 2022 | n/a | n/a | -US$34m |
| Mar 31 2022 | n/a | n/a | -US$49m |
| Dec 31 2021 | US$18m | US$827k | -US$29m |
| Sep 30 2021 | n/a | n/a | -US$48m |
| Jun 30 2021 | n/a | n/a | -US$35m |
| Mar 31 2021 | n/a | n/a | -US$27m |
| Dec 31 2020 | US$4m | US$834k | -US$60m |
| Sep 30 2020 | n/a | n/a | -US$56m |
| Jun 30 2020 | n/a | n/a | -US$42m |
| Mar 31 2020 | n/a | n/a | -US$82m |
| Dec 31 2019 | US$4m | US$780k | -US$76m |
Vergütung im Vergleich zum Markt: AlanDie Gesamtvergütung ($USD3.06M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD2.59M).
Entschädigung vs. Einkommen: AlanDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Alan Auerbach (55 yo)
15.7yrs
Amtszeit
US$3,062,337
Vergütung
Mr. Alan H. Auerbach is the Founder of Puma Biotechnology, Inc. and has been its Executive Chairman since October 4, 2011 and serves as its Chief Executive Officer, President and Secretary since September...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Founder | 15.7yrs | US$3.06m | 13.84% $ 51.2m | |
| CFO & Principal Accounting Officer | 7.5yrs | US$1.24m | 0.32% $ 1.2m | |
| Chief Regulatory Affairs | 8.3yrs | US$1.06m | 0.26% $ 958.5k | |
| Senior Director of Investor Relations | 14.5yrs | keine Daten | keine Daten | |
| Senior Vice President of Marketing | 4.9yrs | keine Daten | keine Daten | |
| Senior Vice President of Sales | no data | keine Daten | keine Daten |
8.3yrs
Durchschnittliche Betriebszugehörigkeit
56yo
Durchschnittliches Alter
Erfahrenes Management: Das Managementteam von PBYI ist erfahren und erfahren (durchschnittliche Amtszeit von 8.3 Jahren).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Founder | 14.6yrs | US$3.06m | 13.84% $ 51.2m | |
| Lead Independent Director | 14.1yrs | US$173.08k | 0.052% $ 191.3k | |
| Independent Director | 8.3yrs | US$158.08k | 0.053% $ 196.3k | |
| Independent Director | 12.6yrs | US$173.08k | 0.034% $ 124.3k | |
| Independent Director | 3.8yrs | US$153.08k | 0.029% $ 108.0k | |
| Independent Director | 10.8yrs | US$165.58k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$155.58k | 0.095% $ 351.8k | |
| Independent Director | 5.8yrs | US$168.08k | 0.13% $ 494.0k |
9.5yrs
Durchschnittliche Betriebszugehörigkeit
62.5yo
Durchschnittliches Alter
Erfahrener Vorstand: PBYIDie Vorstandsmitglieder gelten als erfahren (9.5 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/27 18:42 |
| Aktienkurs zum Tagesende | 2026/05/27 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Puma Biotechnology, Inc. wird von 13 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Yigal Nochomovitz | Citigroup Inc |
| Paul Choi | Goldman Sachs |